-
Article
Open AccessHigh EVI1 and PARP1 expression as favourable prognostic markers in high-grade serous ovarian carcinoma
Mechanisms of development and progression of high-grade serous ovarian cancer (HGSOC) are poorly understood. EVI1 and PARP1, part of TGF-ß pathway, are upregulated in cancers with DNA repair deficiencies with ...
-
Article
Open AccessEVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy
Overexpression of the EVI1 (ecotropic viral integration site 1) oncogene has recently been implicated as a prognostic factor in breast cancer (BC), particularly in triple-negative BC (TNBC). In this study we a...
-
Article
Open AccessIdentification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia
Deregulation of the EVI1 proto-oncogene by the GATA2 distal hematopoietic enhancer (G2DHE) is a key event in high-risk acute myeloid leukemia carrying 3q21q26 aberrations (3q-AML). Upon chromosomal rearrangement,...
-
Article
Open AccessThe leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops
Chromosomal rearrangements are a frequent cause of oncogene deregulation in human malignancies. Overexpression of EVI1 is found in a subgroup of acute myeloid leukemia (AML) with 3q26 chromosomal rearrangements, ...
-
Article
Open AccessHematopoietic stem and progenitor cell-restricted Cdx2 expression induces transformation to myelodysplasia and acute leukemia
The caudal-related homeobox transcription factor CDX2 is expressed in leukemic cells but not during normal blood formation. Retroviral overexpression of Cdx2 induces AML in mice, however the developmental stag...
-
Article
Open AccessDefective homologous recombination DNA repair as therapeutic target in advanced chordoma
Chordomas are rare bone tumors with few therapeutic options. Here we show, using whole-exome and genome sequencing within a precision oncology program, that advanced chordomas (n = 11) may be characterized by gen...
-
Article
Open AccessIntegrative genomic and transcriptomic analysis of leiomyosarcoma
Leiomyosarcoma (LMS) is an aggressive mesenchymal malignancy with few therapeutic options. The mechanisms underlying LMS development, including clinically actionable genetic vulnerabilities, are largely unknow...
-
Article
Genomisch-histologische Analyse eines „cancer of unknown primary“
-
Article
Personalisierte Medizin: Strukturen, Tumorboards, Visionen
Die zunehmende Berücksichtigung molekularer Charakteristika in der Therapieauswahl hat bei etlichen histologisch nicht weiter zu differenzierenden Tumorentitäten zu einer relevanten Prognoseverbesserung geführ...
-
Article
Personalisierte Medizin: Strukturen, Tumorboards, Visionen
Die zunehmende Berücksichtigung molekularer Charakteristika in der Therapieauswahl hat bei etlichen histologisch nicht weiter zu differenzierenden Tumorentitäten zu einer relevanten Prognoseverbesserung geführ...
-
Article
Active medulloblastoma enhancers reveal subgroup-specific cellular origins
Medulloblastoma is a highly malignant paediatric brain tumour, often inflicting devastating consequences on the develo** child. Genomic studies have revealed four distinct molecular subgroups with divergent ...
-
Article
TLR-mediated induction of negative regulatory ligands on dendritic cells
Dendritic cells (DCs) shape T-cell response patterns and determine early, intermediate, and late outcomes of immune recognition events. They either facilitate immunostimulation or induce tolerance, possibly de...
